Jowe Hsieh
Internal Medicine · Granite City, ILNPI 1285629212
Payments from drug & device makers
Across 61 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$145
- Teva Pharmaceuticals USA, Inc.$145
- Merck$143
- AbbVie$59
- Alkermes, Inc.$58
- Lundbeck LLC$40
- plus $299 from 15 others
What the payments were for
- Food & beverage$890100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 10 | $145 |
| Teva Pharmaceuticals USA, Inc. | 8 | $145 |
| Merck | 12 | $143 |
| AbbVie | 4 | $59 |
| Alkermes, Inc. | 4 | $58 |
| Lundbeck LLC | 2 | $40 |
| Viiv Healthcare Company | 2 | $38 |
| Novo Nordisk | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Pfizer | 2 | $24 |
| Boehringer Ingelheim | 2 | $24 |
| Corium, LLC | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Indivior Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| MDD US Operations, LLC | 1 | $12 |
| Dexcom, Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$890 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 85 | $59,559 |
| OzempicSemaglutide | 29 | $34,416 |
| FarxigaDapagliflozin Propanediol | 43 | $30,871 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $15,656 |
| JardianceEmpagliflozin | 18 | $13,983 |
| LinzessLinaclotide | 21 | $11,505 |
| TradjentaLinagliptin | 11 | $9,466 |
| Gabapentin | 198 | $3,840 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 130 | $3,215 |
| Levemir FlexpenInsulin Detemir | 18 | $2,772 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,555 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $2,527 |
| Dipyridamole | 12 | $1,333 |
| Atorvastatin Calcium | 209 | $1,212 |
| Ventolin HfaAlbuterol Sulfate | 11 | $979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $143 | $59,55985 claims |
| Novo NordiskOzempic | $32 | $34,41629 claims |
| Boehringer IngelheimJardiance, Tradjenta | $24 | $23,44929 claims |
| AbbVieLinzess | $59 | $11,50521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Granite City
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.